A Blood Test to Stage Alzheimer’s Disease
A study published in Alzheimer’s & Dementia demonstrates that plasma phosphorylated tau 217 (p-tau217) can accurately predict the pathological staging of Alzheimer’s disease as determined by positron emission tomography (PET). In a cohort of 237 participants, the blood-based biomarker showed excellent performance in detecting early amyloid pathology and intermediate tau pathology. The research identified specific concentration thresholds for p-tau217 that correspond to key disease stages, offering a highly accessible alternative to PET imaging for identifying patients who may be candidates for disease-modifying therapies.
Why it might matter to you:
This work directly advances the clinical utility of blood-based biomarkers for neurodegenerative disease. It provides a concrete framework for translating a proteomic signal into a precise, stage-specific diagnostic tool, which is a core challenge in the field. For your work on clinical actionability, this study offers a validated model of how a single plasma biomarker can be calibrated against gold-standard imaging to create actionable thresholds for patient stratification and therapeutic decision-making.
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
